4 completed, 2 recruiting, 1 terminated. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Vedanta Biosciences, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VE303 for Prevention of Recurrent Clostridioides Difficile Infection VE303, Placebo - Clostridium Difficile, Clostridium Difficile Infections | Phase 3 | Recruiting | Vedanta Biosciences, Inc. | 852 | 2024-05-20 | 2026-09-29 |
| VE202 in Patients With Mild-to-Moderate Ulcerative Colitis VE202, Vancomycin Oral Capsule, VE202 Placebo - Ulcerative Colitis, Colitis, Ulcerative | Phase 2 | Terminated | Vedanta Biosciences, Inc. | 114 | 2023-05-08 | 2025-12-17 |
| VE303 for Treatment of Hepatic Encephalopathy (HE) Placebo, VE303, oral vancomycin - Cirrhosis, Hepatic Encephalopathy | Phase 2 | Completed | Patricia Bloom | 19 | 2021-08-06 | 2025-02-07 |
| Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer VE800, Nivolumab, Vancomycin Oral Capsule - Metastatic Cancer, Melanoma | Phase 1 / Phase 2 | Completed | Vedanta Biosciences, Inc. | 56 | 2020-01-23 | 2025-10-27 |
| VE416 for Treatment of Food Allergy Vancomycin plus VE416 before PNOIT, Vancomycin plus VE416 with PNOIT, Placebo plus VE416 with PNOIT - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Massachusetts General Hospital | 60 | 2019-06-28 | 2023-10-18 |
| Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection VE303, Placebo - Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection | Phase 2 | Completed | Vedanta Biosciences, Inc. | 79 | 2019-02-08 | 2023-07-03 |
| First-in-human Study of VE303 in Healthy Adult Volunteers VE303, Oral Vancomycin - Healthy Volunteers | Phase 1 | Completed | Vedanta Biosciences, Inc. | 39 | 2017-11-28 | 2020-01-27 |
Clostridium Infections (2) · Colitis, Ulcerative (1) · Colorectal Neoplasms (1) · Dysentery (1) · Fibrosis (1) · Hepatic Encephalopathy (1) · Melanoma (1) · Neoplasm Metastasis (1) · Peanut Hypersensitivity (1) · Stomach Neoplasms (1)
Vancomycin (5) · Nivolumab (1)
United States (7) · Australia (2) · Bulgaria (2) · Canada (2) · Czechia (2) · Hungary (2) · Netherlands (2) · Poland (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · Denmark (1) · France (1) · Georgia (1) · Germany (1)
Darrell Pardi, MD (1) · Judy Wang, MD (1) · Patricia Bloom, MD (1) · Wayne G Shreffler, MD, PhD (1)